论文部分内容阅读
新的ＩＮＳＩＧＨＴ研究显示 ,拜耳公司的长效硝苯地平 (ｎｉｆｅｄｉｐｉｎｅ ,ＡｄａｌａｔＬＡ)在减少伴有其他高危并发症的高血压病人心血管病的发病率和死亡率上与利尿剂配伍组有同样效果。目前 ,国际上治疗高血压的指导原则很多。 1999年公布的新的欧洲指导原则认为 ,所
The new INSIGHT study shows that Bayer’s long-acting nifedipine (AdalatLA) has the same effect as diuretics in reducing the incidence and mortality of cardiovascular disease in hypertensive patients with other high-risk compli- cations. At present, there are many guiding principles for the treatment of hypertension in the world. The new European guidelines published in 1999 considered